This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

A Better Way to Play Pharma

So the yields are in the same ballpark, and both TIPS and pharmaceuticals have limited upside.

What about the downside for health? This idea would make no sense if Pfizer and Merck (MRK - Get Report) plummet from here.

But here is an anecdote that may point to a bottom. When I first wrote about my Pfizer revenue theory a year and a half ago on another Web site, I received an incredible amount of hate email. When I repeated the idea in a Columnist Conversation post last week, I only got one email that mildly disagreed. This leads me to think the selling could be about done.

Three things might be enough to tie this theory together: similar yield, limited upside and limited downside.

If the broad market provides below-average returns for the next few years, as some contend, and if my thoughts about pharmaceuticals hold water, it might result in the pharmaceutical-centric ETFs averaging 2%-3% returns plus the dividend. That's not much different from what TIPS are likely to do.

But pharma ETFs offer something TIPS don't. Despite what anyone thinks about the fundamentals, the entire sector could rally significantly at any time for no reason at all. This has happened repeatedly throughout market history. Pharma-centric ETFs should participate to some degree in a broad market rally -- this can not be expected of TIPS.

This idea makes some sense if you believe that, after being cut in half or worse, domestic pharma stocks have now seen most of the selling.

At the time of publication, Nusbaum was long JNJ, although positions may change at any time.

Roger Nusbaum is a portfolio manager with Your Source Financial of Phoenix, Ariz., and the author of Random Roger's Big Picture Blog. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Nusbaum appreciates your feedback; click here to send him an email.

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
PPH $71.06 0.51%
XLV $73.76 0.99%
C $51.76 1.50%
MRK $58.41 1.10%
PFE $34.82 0.84%

Markets

DOW 17,976.24 +263.58 1.49%
S&P 500 2,078.50 +17.48 0.85%
NASDAQ 4,932.2780 +41.0590 0.84%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs